Skip to main content
. 2020 Feb 7;38(10):1059–1069. doi: 10.1200/JCO.19.01027

FIG 3.

FIG 3.

Kaplan-Meier plots of event-free survival (EFS) in MK-2206 (blue) and control (red) arms for (A) all participants; (B) participants with hormone receptor-negative (HR−) breast cancer; (C) human epidermal growth factor receptor 2–positive (HER2+) breast cancer; and (D) HER2+/HR– breast cancer. Hazard ratios and 95% CIs are provided; however, caution is warranted in interpreting the results because of the low number of patients in each subtype and the fact that I-SPY 2 is not powered for survival end points. Ref, reference.